Thomas Leung serves as Chief Financial Officer of the Company. Mr. Leung has served as our chief financial officer since April 2019. Prior to joining us, Mr. Leung served as vice president, business operations at Counsyl, Inc., a genetic screening company acquired by Myriad Genetics, Inc., where he held leadership roles in finance, strategy, billing operations and sales operations from August 2013 to April 2019. Prior to Counsyl, Mr. Leung served as a vice president of TPG Capital in San Francisco and Hong Kong, where he was responsible for sourcing investments, executing acquisitions and financings and managing portfolio companies. Mr. Leung began his career in investment banking at Morgan Stanley & Co. He holds an M.B.A. from Harvard Business School and received a B.S. in economics and biomedical engineering from Yale University.
As the Chief Financial Officer of Adverum Biotechnologies Inc, the total compensation of Thomas Leung at Adverum Biotechnologies Inc is 2,435,400$. There are 1 executives at Adverum Biotechnologies Inc getting paid more, with Leone Patterson having the highest compensation of 2,830,320$.
Thomas Leung is 39, he's been the Chief Financial Officer of Adverum Biotechnologies Inc since 2019. There are 17 older and 1 younger executives at Adverum Biotechnologies Inc. The oldest executive at Adverum Biotechnologies Inc is Richard Spivey, 69, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK, CA, 94025.
Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over 1,591,374$ worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth 4,153,055$ . The most active insiders traders include Patrick Machado、Braden Michael Leonard、Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of 200,186$. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth 613,470$.
adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include: